1 Contained use of gene technology
We find that the contained use of gene technology is an
important tool in the identification, development, and production of
pharmaceuticals for patients. These pharmaceuticals could not
otherwise be provided in sufficient quantity or quality.
2 Use of GMOs
We only use GMOs in the lowest risk category for production and
the final products do not contain genetically modified cells or genes.
3 Antibiotic resistance genes
We use production strains without antibiotic resistance genes
whenever technically possible and practically feasible.
4 Accidental release of GMOs
We recognise the concern about accidental release of GMOs to
the environment and has implemented appropriate measures to ensure
compliance with regulations set by the authorities.
5 Regulation and public concerns
We support the proper regulation of the use of gene technology
and the principle that public concerns are adequately addressed.
6 Precautionary principle
We apply the Precautionary Principle in the use of gene
technology by conducting risk assessments prior to use.
7 International standards
We actively participate in the development of relevant
international standards for gene technology.
8 Transparency and openness
We support transparency and openness in relation to the use of
gene technology and continues to report publicly on our use of the technology.